<DOC>
	<DOCNO>NCT00314561</DOCNO>
	<brief_summary>Pioglitazone rosiglitazone use treatment diabetic patient . Thiazolidinediones increase insulin sensitivity show favorable effect blood glucose level lipid profile . The effect two different thiazolidinediones atherosclerotic inflammatory marker compare prospective manner . The purpose prospective , randomize , open-label , crossover trial compare effect pioglitazone rosiglitazone atherosclerotic inflammatory marker patient metabolic syndrome .</brief_summary>
	<brief_title>The Effect Pioglitazone Rosiglitazone Atherosclerotic Inflammatory Markers Patients With Metabolic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Patients least 3 metabolic syndrome criterion AsianPacific ATP III guideline : fasting blood glucose ≥ 110 mg/dl , systolic blood pressure ≥ 130 mmHg diastolic blood pressure ≥ 85 mmHg , triglyceride ≥ 150 mg/dl , HDLcholesterol &lt; 40 mg/dl men &lt; 50 mg/dl woman . Age : 18 year Hypertensive patient use ACE inhibitor ARB Hyperlipidemic patient use statin fenofibrate Patients contraindication treatment thiazolidinediones Pregnant lactate patient Chronic alcohol drug abuse Hepatic dysfunction Renal dysfunction Heart failure ( EF &lt; 50 % ) Expected life expectancy &lt; 1 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>Rosiglitazone</keyword>
	<keyword>Pioglitazone</keyword>
	<keyword>FMD</keyword>
	<keyword>PWV</keyword>
	<keyword>atherosclerosis</keyword>
</DOC>